Delayed by the coronavirus outbreak, a wave of undiagnosed cancer cases may be building
A sharp upswing in cancer diagnoses, harder-to-treat advanced cancers, and cancer deaths may be among the many unexpected consequences of the coronavirus pandemic.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Facing an onslaught of COVID-19 patients, hospitals have been forced to reduce or delay cancer screening and diagnostic tests. And symptomatic but undiagnosed cancer patients have been reluctant to seek care, out of fear of being infected with the coronavirus in a clinical setting.
The result, as Cleveland Clinic Cancer Center hematologist/oncologist Mikkael Sekeres, MD, MS, warns in his latest New York Times column, may be a coming surge of cancer cases, even as COVID-19 cases are leveling off.
“Those of us in oncology fear a second pandemic of ‘new’ cancer diagnoses, which in reality have been brewing for months,” writes Dr. Sekeres, who is Director of the Leukemia Program and Vice-chair for Clinical Research.. “And not just new cancers but more advanced cancers. It is entirely possible that, in the latter part of 2020 and into 2021, we will see a shift to higher stages of cancer because of these delays in diagnoses. We may lose our window to intervene early, when cancer is still at an early stage, and eliminate it.”
Read Dr. Sekeres’ full column here.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients